Abstract
BACKGROUND: Emerging work has examined neurodevelopmental outcomes following prenatal exposure to per- and polyfluoroalkyl substances (PFAS), but few studies have assessed associations with autism spectrum disorder (ASD). OBJECTIVES: Our objective was to estimate associations of maternal prenatal PFAS concentrations with ASD and intellectual disability (ID) in children. METHODS: Participants were from a population-based nested case–control study of children born from 2000 to 2003 in southern California, including children diagnosed with ASD (n = 553), ID without autism (n = 189), and general population (GP) controls (n = 433). Concentrations of eight PFAS from stored maternal sera collected at 15–19 wk gestational age were quantified and compared among study groups. We used logistic regression to obtain adjusted odds ratios for the association between prenatal PFAS concentrations (parameterized continuously and as quartiles) and ASD versus GP controls, and separately for ID versus GP controls. RESULTS: Geometric mean concentrations of most PFAS were lower in ASD and ID groups relative to GP controls. ASD was not significantly associated with prenatal concentrations of most PFAS, though significant inverse associations were found for perfluorooctanoate (PFOA) and perfluorooctane sulfonate (PFOS) [adjusted ORs for the highest vs. lowest quartiles 0.62 (95% CI: 0.41, 0.93) and 0.64 (95% CI: 0.43, 0.97), respectively]. Results for ID were similar. CONCLUSIONS: Results from this large case–control study with prospectively collected prenatal measurements do not support the hypothesis that prenatal exposure to PFAS is positively associated with ASD or ID.
| Original language | English (US) |
|---|---|
| Article number | 017001 |
| Journal | Environmental Health Perspectives |
| Volume | 126 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 1 2018 |
Fingerprint
ASJC Scopus subject areas
- Public Health, Environmental and Occupational Health
- Health, Toxicology and Mutagenesis
Cite this
Prenatal maternal serum concentrations of per- and polyfluoroalkyl substances in association with autism spectrum disorder and intellectual disability. / Lyall, Kristen; Yau, Vincent M.; Hansen, Robin L; Kharrazi, Martin; Yoshida, Cathleen K.; Calafat, Antonia M.; Windham, Gayle; Croen, Lisa A.
In: Environmental Health Perspectives, Vol. 126, No. 1, 017001, 01.01.2018.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Prenatal maternal serum concentrations of per- and polyfluoroalkyl substances in association with autism spectrum disorder and intellectual disability
AU - Lyall, Kristen
AU - Yau, Vincent M.
AU - Hansen, Robin L
AU - Kharrazi, Martin
AU - Yoshida, Cathleen K.
AU - Calafat, Antonia M.
AU - Windham, Gayle
AU - Croen, Lisa A.
PY - 2018/1/1
Y1 - 2018/1/1
N2 - BACKGROUND: Emerging work has examined neurodevelopmental outcomes following prenatal exposure to per- and polyfluoroalkyl substances (PFAS), but few studies have assessed associations with autism spectrum disorder (ASD). OBJECTIVES: Our objective was to estimate associations of maternal prenatal PFAS concentrations with ASD and intellectual disability (ID) in children. METHODS: Participants were from a population-based nested case–control study of children born from 2000 to 2003 in southern California, including children diagnosed with ASD (n = 553), ID without autism (n = 189), and general population (GP) controls (n = 433). Concentrations of eight PFAS from stored maternal sera collected at 15–19 wk gestational age were quantified and compared among study groups. We used logistic regression to obtain adjusted odds ratios for the association between prenatal PFAS concentrations (parameterized continuously and as quartiles) and ASD versus GP controls, and separately for ID versus GP controls. RESULTS: Geometric mean concentrations of most PFAS were lower in ASD and ID groups relative to GP controls. ASD was not significantly associated with prenatal concentrations of most PFAS, though significant inverse associations were found for perfluorooctanoate (PFOA) and perfluorooctane sulfonate (PFOS) [adjusted ORs for the highest vs. lowest quartiles 0.62 (95% CI: 0.41, 0.93) and 0.64 (95% CI: 0.43, 0.97), respectively]. Results for ID were similar. CONCLUSIONS: Results from this large case–control study with prospectively collected prenatal measurements do not support the hypothesis that prenatal exposure to PFAS is positively associated with ASD or ID.
AB - BACKGROUND: Emerging work has examined neurodevelopmental outcomes following prenatal exposure to per- and polyfluoroalkyl substances (PFAS), but few studies have assessed associations with autism spectrum disorder (ASD). OBJECTIVES: Our objective was to estimate associations of maternal prenatal PFAS concentrations with ASD and intellectual disability (ID) in children. METHODS: Participants were from a population-based nested case–control study of children born from 2000 to 2003 in southern California, including children diagnosed with ASD (n = 553), ID without autism (n = 189), and general population (GP) controls (n = 433). Concentrations of eight PFAS from stored maternal sera collected at 15–19 wk gestational age were quantified and compared among study groups. We used logistic regression to obtain adjusted odds ratios for the association between prenatal PFAS concentrations (parameterized continuously and as quartiles) and ASD versus GP controls, and separately for ID versus GP controls. RESULTS: Geometric mean concentrations of most PFAS were lower in ASD and ID groups relative to GP controls. ASD was not significantly associated with prenatal concentrations of most PFAS, though significant inverse associations were found for perfluorooctanoate (PFOA) and perfluorooctane sulfonate (PFOS) [adjusted ORs for the highest vs. lowest quartiles 0.62 (95% CI: 0.41, 0.93) and 0.64 (95% CI: 0.43, 0.97), respectively]. Results for ID were similar. CONCLUSIONS: Results from this large case–control study with prospectively collected prenatal measurements do not support the hypothesis that prenatal exposure to PFAS is positively associated with ASD or ID.
UR - http://www.scopus.com/inward/record.url?scp=85041381080&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041381080&partnerID=8YFLogxK
U2 - 10.1289/EHP1830
DO - 10.1289/EHP1830
M3 - Article
C2 - 29298162
AN - SCOPUS:85041381080
VL - 126
JO - Environmental Health Perspectives
JF - Environmental Health Perspectives
SN - 0091-6765
IS - 1
M1 - 017001
ER -